Immunovant, Inc. (NASDAQ:IMVT – Get Rating) has been assigned an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among […]
Immunovant, Inc. (NASDAQ:IMVT – Get Rating) has been given an average recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target […]
Immunovant (NASDAQ:IMVT – Get Rating) had its price target lifted by Bank of America from $26.00 to $28.00 in a research note released on Tuesday, The Fly reports. Several other equities research analysts have also issued reports on the company. Piper Sandler began coverage on Immunovant in a research note on Friday, March 31st. They […]
Immunovant (NASDAQ:IMVT – Get Rating) had its price target upped by Chardan Capital from $21.00 to $32.00 in a research note published on Monday, The Fly reports. Chardan Capital also issued estimates for Immunovant’s FY2024 earnings at ($1.53) EPS. Several other research firms have also weighed in on IMVT. SVB Leerink raised their price objective […]
Immunovant, Inc. (NASDAQ:IMVT – Get Rating) – Research analysts at Chardan Capital issued their FY2024 EPS estimates for Immunovant in a report released on Monday, May 22nd. Chardan Capital analyst M. Barcus expects that the company will earn ($1.53) per share for the year. The consensus estimate for Immunovant’s current full-year earnings is ($1.83) per […]